Secukinumab自动注射器维持中重度斑块状银屑病52周疗效:JUNCTURE随机对照试验结果
JUNCTURE随机对照试验评估中重度斑块状银屑病患者自我注射secukinumab 300mg或150mg的疗效、安全性与可接受性。52周时300mg组PASI 75/90/100应答率分别为81.4%/64.1%/38.8%,150mg组为75.2%/57.4%/33.1%。自动注射器可接受性至48周保持较高,300mg组不良事件比例高于150mg组。
要点
- 自我注射secukinumab 300mg和150mg至52周维持较高PASI应答。
- 300mg组PASI 75/90/100应答率分别为81.4%/64.1%/38.8%。
- 150mg组PASI 75/90/100应答率分别为75.2%/57.4%/33.1%。
核心结论
- 自动注射器自我注射secukinumab具有稳健且持续的疗效、良好的安全性特征和高可接受性。
研究设计与样本
- 随机对照试验,中重度斑块状银屑病患者随机接受secukinumab 300mg、150mg或安慰剂自我注射。
主要发现
- 52周时300mg组PASI 75/90/100应答率分别为81.4%/64.1%/38.8%,IGA mod 2011 0/1应答率为69.6%(多重插补)。
- 52周时150mg组PASI 75/90/100应答率分别为75.2%/57.4%/33.1%,IGA mod 2011 0/1应答率为60.2%(多重插补)。
- 患者对自动注射器的可接受性至48周保持较高。
- 不良事件发生率300mg组为88.6%,150mg组为78.7%。
关键数值与推荐
- 疗效评估采用PASI 75/90/100和IGA mod 2011 0/1应答。
- 自动注射器可用性通过自我注射评估问卷至48周评估。
临床怎么用
- 中重度斑块状银屑病患者可考虑使用自动注射器自我注射secukinumab 300mg或150mg以维持长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: User satisfaction is an important factor associated with treatment adherence in chronic diseases including moderate-to-severe psoriasis. OBJECTIVE: To evaluate the efficacy, safety and patient acceptability of 300 and 150 mg secukinumab - a fully human anti-interleukin-17A monoclonal antibody that has demonstrated efficacy in the treatment of patients with moderate-to-severe plaque psoriasis - self-administered by autoinjection. METHODS: Patients with moderate-to-severe plaque psoriasis were randomized to secukinumab 300 mg, secukinumab 150 mg or placebo self-administered by autoinjection at baseline, Weeks 1, 2 and 3 and then every 4 weeks from Week 4 to Week 48. Efficacy responses [≥75/90/100% improvement in Psoriasis Area and Severity Index (PASI 75/90/100) and clear/almost clear skin by Investigator's Global Assessment 2011 modified version (IGA mod 2011 0/1)] were measured at Week 52. Patient-reported usability of the autoinjector was evaluated by the self-injection assessment questionnaire to Week 48. RESULTS: At Week 52 with secukinumab 300 mg, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 81.4/64.1/38.8% and 69.6% of patients, respectively, by multiple imputation. At Week 52 with secukinumab 150 mg, PASI 75/90/100 and IGA mod 2011 0/1 responses were achieved by 75.2/57.4/33.1% and 60.2% of patients, respectively, by multiple imputation. Patient-assessed acceptability of the autoinjector remained high to Week 48. The proportion of patients experiencing adverse events was greater with secukinumab 300 mg (88.6%) than with secukinumab 150 mg (78.7%). CONCLUSION: Self-administration of secukinumab using an autoinjector was associated with robust and sustained efficacy, a good safety profile and high acceptability.
引用
- Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017. PMID: 28111801. doi:10.1111/jdv.14073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。